Cannabis Use Disorder and Medical Edibles: The Diagnosis a Medical Card Makes More Likely

Cannabis causes a recognised psychiatric disorder, and a site that sells the idea of edibles as medicine owes its readers that sentence before any other. The American Psychiatric Association's manual lists cannabis use disorder alongside the alcohol and opioid versions, scored on the same 11 criteria. About three in ten Americans who used cannabis in the past year met the older DSM-IV definition in the 2012-2013 national NESARC-III survey, and a 2024 meta-analysis found the rate among medical users was no lower than among recreational ones.

Our view: a medical card is a risk factor for this disorder, and the evidence for that is stronger than the evidence for several of the conditions the card is issued for. In the only randomized trial of card ownership, run in Boston, people handed a card on day one developed cannabis use disorder at twice the rate of people told to wait 12 weeks, and their pain, anxiety and depression did no better. A nightly 5mg gummy is a long way from a diagnosis. Anyone taking one should still know the criteria, notice the drift, and say the words to the clinician who signed the certification.

What is cannabis use disorder?

A DSM-5 diagnosis for cannabis use that keeps causing problems, scored on 11 criteria covering loss of control, craving, harm to work and relationships, tolerance and withdrawal. Two or three criteria in a year counts as mild, four or five as moderate, and six or more as severe, per the DSM-5 work group's 2013 rationale paper.

That paper, by Hasin and colleagues, explains the rewrite. The old split between abuse and dependence was merged into one disorder on data from more than 200,000 study participants, legal problems were dropped as a criterion, craving was added, and cannabis withdrawal became a recognised syndrome for the first time. The mild band is wide on purpose (the work group wanted milder cases caught in primary care).

For a patient, tolerance and withdrawal are the criteria that tend to arrive first, and the easiest to explain away as the original condition coming back.

How common is cannabis use disorder in medical cannabis patients?

About one in four. Dawson's 2024 meta-analysis of 14 studies and 3,681 medical users across five countries put the DSM-5 rate at 29% for people using in the past 6 to 12 months and 25% across all time windows, comparable to recreational users. Chronic pain and mental health conditions went with higher risk.

The national baseline is in the same range. In the 2012-2013 NESARC-III survey of 36,309 American adults, Hasin's team found 30.6% of past-year users met DSM-IV criteria for a marijuana use disorder. Using the new DSM-5 definition, 2.5% of all adults had the disorder in the past year and 6.3% at some point in their lives, and those with a 12-month diagnosis used on an average of 225 days a year. Only 13.2% of the people with a lifetime diagnosis had ever been to professional treatment or a 12-step program.

The number that should stop a medical site in its tracks comes from Massachusetts General Hospital. Gilman and colleagues randomized 186 adults who wanted a card for pain, insomnia, anxiety or depression. Daily users and anyone who already had cannabis use disorder were screened out. The 105 allowed to get a card at once chose their own dispensary products, doses and schedules. After 12 weeks, 17.1% of them had developed cannabis use disorder, against 8.6% of the 81 who waited, an adjusted odds ratio of 2.88, with the clearest effect in people who came in for anxiety or depression. Pain, anxiety and depression scores did not improve. Self-rated insomnia did.

What does cannabis withdrawal feel like, and how long does it last?

Irritability, anxiety, poor sleep with vivid dreams, low appetite, restlessness and low mood, plus at least one physical symptom such as stomach pain, shakiness, sweating or headache. Connor's 2021 review puts the start at 24 to 48 hours after stopping, the peak within the first week, and the end at one to two weeks.

Bahji's 2020 meta-analysis in JAMA Network Open pooled 47 studies and 23,518 people with regular or dependent use and found withdrawal in 47% of them. The spread by setting is the useful part: 17% in general population samples, 54% in outpatient clinics and 87% in inpatients. Daily use was associated with higher rates. Budney's 2004 review, which laid the groundwork for the DSM-5 syndrome, described the symptoms as mainly emotional and behavioral and their time course as similar to other drug withdrawals, which is a polite way of saying that the people who called it a myth were wrong.

For an edible patient the trap is the overlap. A sleep patient who stops and sleeps badly for a week, or an anxiety patient who feels edgy on day three, reads the symptom as the original condition returning. Sometimes it is. On Connor's timeline withdrawal has largely run its course by the end of the second week, and an underlying condition has not, which is why two weeks is the point at which the two start to separate.

Is CBD good for cannabis withdrawal?

One trial says it helps a little, at a dose no gummy aisle is built for. In Freeman's 2020 Lancet Psychiatry trial, 800mg of CBD a day lowered withdrawal scale scores against placebo during a cessation attempt, and 400mg and 800mg both cut cannabis use more than placebo did. Withdrawal was a secondary outcome.

The details matter. The London team gave 82 people with DSM-5 cannabis use disorder four weeks of synthetic CBD at 99.9% purity in capsules, two capsules twice a day, alongside motivational interviewing for everyone. The 200mg dose was dropped at the interim analysis as inefficacious. At 400mg, people had 0.48 more cannabis-free days a week than on placebo, though their sleep quality scores got worse. At 800mg the withdrawal score fell by 1.26 points during treatment, and by the final follow-up the 800mg group's cannabis use looked like placebo's. For scale, 800mg is 32 gummies at 25mg apiece, every day, a jar-a-day habit.

LOTUS, a University of Colorado Boulder trial of hemp-derived CBD in people with cannabis use disorder who use concentrates, published its protocol in 2024, and no results were indexed in PubMed when this page was checked. Until a larger trial reports, the honest answer to the question on the jar is that CBD at a pharmaceutical dose helped in one phase 2 study, and that the 25mg gummy sold for withdrawal has not been tested at all.

What treatments have evidence for cannabis use disorder?

Talking treatments, first. Connor's review names cognitive behavioral therapy, motivational enhancement therapy and contingency management (small rewards for negative urine tests) as first-line for adolescents and adults, while noting that lasting abstinence is not the usual outcome. No medication is approved, and a 2019 Cochrane review rated every drug tested as incomplete evidence.

Sherman and McRae-Clark's 2016 review found the three combined gave the best abstinence results, still modest. The medication trials are where it gets strange.

The N-acetylcysteine pair is the cautionary tale. The adolescent trial called itself the first positive pharmacotherapy trial for cannabis dependence in any age group, and the adult replication, nearly three times the size, landed on a difference of 0.1 percentage points. Gabapentin's result came from 50 people, and the 2019 Cochrane review judged the gabapentin evidence insufficient for any estimate of effectiveness.

And then there is nabiximols, the strongest result in the table, which is THC and CBD in a mouth spray. The Sydney participants averaged 47.5mg of THC a day from it, under weekly clinical review, and used street cannabis on 18.6 fewer days over 12 weeks than the placebo group. The most promising medication for cannabis dependence turns out to be cannabis, measured, supervised and paired with counseling. The 2019 Cochrane review still filed THC preparations as experimental. Nobody in that trial was choosing a dose from a dispensary shelf.

Do daily high-dose edibles make dependence more likely?

Frequency and dose are the two levers the evidence keeps pointing at. Bahji found daily use tied to more withdrawal, and Connor's review notes that legal markets have made high-potency products, edibles among them, cheaper and easier to get. On our dosing guide, 15 to 30mg is a high dose and 30mg and above very high.

The edible version of drift is quiet: one gummy becomes two, then a 100mg bar portioned by eye. The dosing guide sets out the tiers, and our edible tolerance break guide covers what a reset looks like for someone who takes edibles for a symptom, including the finding that receptor availability recovers in days. A break that keeps failing is information worth taking to a clinician.

One more signal deserves its own sentence. Cannabinoid hyperemesis syndrome, cycles of severe vomiting in regular users, is a reason to see a clinician. Connor's review notes that almost all patients with it are heavy weekly users and that 90% report hot baths and stopping cannabis relieve it. A patient taking a nightly edible for nausea is the one most likely to miss it, and our chemotherapy nausea page covers that overlap.

What should a medical cannabis patient do if they think they are dependent?

Count the criteria honestly, then tell the clinician who certified the card or prescribes your other medication. Withdrawal that disrupts sleep or work, and cyclic vomiting, are reasons to see a clinician. SAMHSA's National Helpline, 1-800-662-4357, is free, confidential and open 24 hours a day for treatment referral and information.

In the Boston trial the clearest rise in the disorder came in people seeking cannabis for anxiety or depression, so patients with those conditions have the most reason to raise it. Our pages on psychosis risk, alcohol use disorder and opioid use disorder cover the situations where cannabis meets another psychiatric or addiction diagnosis.